Aratana Therapeutics, Inc. Receivables Turnover Ratio (PETX), from the first quarter 2019 to the first quarter 2018 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Aratana Therapeutics, Inc.  (PETX)
 

Aratana Therapeutics Accounts Receivables Turnover Ratio from the first quarter 2019 to the first quarter 2018

Quarterly Results, Trends, Rankings, Statistics


Aratana Therapeutics, Inc.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2019 to a ratio of 5.26, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Aratana Therapeutics in Mar 31 2019 quarter, has decreased to 69 days, compared to 70 days, in the Dec 31 2018 quarter.

If we take a look into Healthcare sector 348 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2019 from 2678 to 2823.

What is Receivable Turnover Ratio?
What is Aratana Therapeutics, Inc. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PETX Receivables Turnover Ratio (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter		 (Jun 30 2018)
II. Quarter		 (Mar 31 2018)
I. Quarter
Y / Y Receivable Change 99.3 % -8.4 % 107.47 % -42.06 % -31.11 %
Y / Y Revenue Change 82.04 % -53.08 % 249.75 % -4.85 % 6.53 %
Receivable Turnover Ratio (TTM) 5.26 5.24 6.01 5.98 5.39
PETX's Total Ranking # 2823 # 2678 # 2684 # 2683 # 2823
Accounts Receivable average collection period days 69 70 61 61 68
Seq. Receivable Change 120.46 % -88.74 % 590.55 % 16.28 % 1.33 %
Seq. Revenue Change 50.02 % -77.24 % 339.18 % 21.4 % -61.34 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 127
Healthcare Sector # 349
Overall Market # 2823

Receivable Turnover Ratio Statistics
High Average Low
1488.23 128.67 -0.09
(Sep 30 2016)   (Sep 30 2014)





PETX Company Profile • Back to PETX Efficiency Comparisons • Compare PETX Receivables Turnover Ratio to its Competitors

Financial Statements
Aratana Therapeutics's Accounts Receivable $ 5 Millions Visit PETX's Balance sheet
Aratana Therapeutics's Sales TTM $ 39 Millions Visit PETX's Income Statement
Sources of PETX's Revenues Visit PETX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PETX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PETX's Growth Rates PETX's Roa PETX's Inventory Turnover Ratio PETX's Dividend Comparisons
PETX's Profitability Ratios PETX's Roi PETX's Asset Turnover Ratio PETX's Dividend Growth
PETX's Valuation Ratios PETX's Roe PETX's Financial Strength Ratios PETX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2019, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Mar 31 2019 Receivable at quarter ending Mar 31 2019
Spero Therapeutics Inc   21.51 $ 10.531  Millions$ 0.490  Millions
Geovax Labs Inc   20.87 $ 1.549  Millions$ 0.074  Millions
Vtv Therapeutics Inc   19.90 $ 11.291  Millions$ 0.568  Millions
Tearlab Corp  19.76 $ 24.083  Millions$ 1.219  Millions
Plx Pharma Inc   19.47 $ 0.989  Millions$ 0.051  Millions
Seres Therapeutics Inc   18.97 $ 31.617  Millions$ 1.667  Millions
Premier Biomedical Inc  18.89 $ 0.035  Millions$ 0.002  Millions
Endonovo Therapeutics Inc   18.38 $ 0.121  Millions$ 0.007  Millions
Immunogen inc   18.14 $ 44.030  Millions$ 2.428  Millions
Cv Sciences Inc   18.07 $ 55.084  Millions$ 3.048  Millions
Traws Pharma inc   17.64 $ 0.732  Millions$ 0.041  Millions
Fortress Biotech Inc   17.39 $ 142.995  Millions$ 8.223  Millions
Valion Bio Inc   17.31 $ 0.264  Millions$ 0.015  Millions
Regenxbio Inc   17.12 $ 86.998  Millions$ 5.081  Millions
Fate Therapeutics Inc   16.92 $ 6.346  Millions$ 0.375  Millions
Healthlynked Corp  16.71 $ 2.078  Millions$ 0.124  Millions
Imac Holdings Inc   16.66 $ 2.770  Millions$ 0.166  Millions
Paratek Pharmaceuticals Inc   16.63 $ 18.705  Millions$ 1.124  Millions
Biocorrx Inc   16.57 $ 0.294  Millions$ 0.018  Millions
Vystar Corporation  16.00 $ 0.530  Millions$ 0.033  Millions
Rigel Pharmaceuticals Inc  15.91 $ 58.020  Millions$ 3.646  Millions
Miragen Therapeutics Inc   15.90 $ 3.974  Millions$ 0.250  Millions
Chemed Corporation  15.46 $ 1,805.506  Millions$ 116.821  Millions
Tvardi Therapeutics Inc   15.26 $ 17.851  Millions$ 1.170  Millions
Chimerix Inc   15.22 $ 8.774  Millions$ 0.577  Millions
Emmaus Life Sciences Inc   15.11 $ 1.581  Millions$ 0.105  Millions
Ainos Inc   14.99 $ 0.025  Millions$ 0.002  Millions
Akebia Therapeutics Inc   14.23 $ 234.478  Millions$ 16.480  Millions
Viskase Holdings inc   14.13 $ 6.852  Millions$ 0.485  Millions
Otonomy Inc   14.06 $ 0.636  Millions$ 0.045  Millions

Date modified: 2026-08-29T17:20:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.